Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
184 hedge funds and large institutions have $2.83B invested in Medicines Co in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 71 increasing their positions, 54 reducing their positions, and 27 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 54
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
2% less funds holding
Funds holding: 188 → 184 (-4)
11% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 27
13% less call options, than puts
Call options by funds: $58M | Put options by funds: $66.6M
20% less capital invested
Capital invested by funds: $3.52B → $2.83B (-$688M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$19.1M |
| 2 |
TBC
Three Bays Capital
Boston,
Massachusetts
|
+$18.4M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$17.8M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$14.9M |
| 5 |
BlackRock
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$40.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$35.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$27.3M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$14.3M |
| 5 |
JP Morgan Chase
New York
|
-$12.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
201
Shelton Capital Management
Denver,
Colorado
| – | -$239K | -6,505 | Closed |
|
202
Man Group
London,
United Kingdom
| – | -$222K | -6,054 | Closed |
|
203
CIBC Asset Management
Toronto,
Ontario, Canada
| – | -$210K | -5,709 | Closed |
|
|
WT
204
Washington Trust
Westerly,
Rhode Island
| – | -$92K | -2,500 | Closed |
|
|
SO
205
STRS Ohio
Columbus,
Ohio
| – | -$90.4K | -2,400 | Closed |
|
206
Envestnet Asset Management
Chicago,
Illinois
| – | -$42K | -1,128 | Closed |
|
|
TAM
207
Tiverton Asset Management
Wilimington,
Delaware
| – | -$36K | -975 | Closed |
|
|
GT
208
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$14K | -369 | Closed |
|
|
YWP
209
YorkBridge Wealth Partners
New York
| – | -$3K | -81 | Closed |
|
|
PCG
210
Private Capital Group
West Hartford,
Connecticut
| – | -$2K | -61 | Closed |
|
|
CAG
211
Csenge Advisory Group
Clearwater,
Florida
| – | +$754 | +20 | New |
|
MDCO Hedge Fund Activity: Q3 2018 in Review
184 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q3 2018, worth a combined $2.83B — down 20% from $3.52B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MDCO and 24 opened new positions — a net loss of 3 holders — while 54 trimmed existing stakes and 71 added.
The largest buyer was Westfield Capital Management, adding an estimated $19.1M. The largest seller was PointState Capital, cutting an estimated $40.8M.
- 184 institutional investors held Medicines Co (MDCO) as of Q3 2018, down from 188 in Q2 2018.
- Funds reported $2.83B of Medicines Co stock for Q3 2018, down 20% quarter-over-quarter.
- 24 funds opened new Medicines Co positions in Q3 2018 and 27 closed out, a net change of -3 holders.
- The largest Medicines Co buyer in Q3 2018 was Westfield Capital Management, an estimated $19.1M added.
- The largest Medicines Co seller in Q3 2018 was PointState Capital, an estimated $40.8M sold.
Based on aggregated 13F filings for Q3 2018.